On November 26, 2021, StageZero Life Sciences Ltd. (“StageZero”) (TSX: SZLS) announced that it closed its previously announced private placement of its Common Shares and Warrants to purchase Common Shares with institutional investors for gross proceeds of approximately CAD$4.2 million. StageZero issued 9,375,002 Common Shares and Warrants to purchase up to an aggregate of 9,375,002 Common Shares at a purchase price of CAD$0.448 per Common Share and associated Warrant.
StageZero was represented by WeirFoulds, with a team consisting of Securities Law Partner Rob Eberschlag, Associate Dhananjay (Jay) Tomar and Law Clerk Katie Liu.
StageZero is a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions.
WeirFoulds is pleased to have assisted StageZero in the closing of this financing.
To learn more about our Securities Practice Group or to contact one of our securities lawyers, visit our securities practice group overview page.